BG
Catalysts
Key Risks
The Opportunity
Bunge is one of the four giant companies that sit between the world's farmers and its food supply. They buy crops like soybeans and grain, ship them around the globe, crush the beans into oil and meal, and sell those ingredients to food companies, animal feed producers, and biofuel makers. It's not glamorous - margins are razor-thin (around 5 cents on every dollar of revenue) - but it's essential infrastructure. Think of them as the plumbing of the global food system.
Last year, Bunge pulled off the biggest deal in its history by merging with Viterra, a Canadian grain trader owned by Glencore and a Canadian pension fund. This roughly doubled the size of the company's balance sheet and made Bunge the second-largest agricultural trader in the world. The integration is going well so far - cost savings from combining operations are running ahead of plan. But the deal also loaded up the balance sheet with debt, and the company is temporarily burning through cash rather than generating it. That's the tension: the long-term position is stronger, but the short-term financial picture looks strained.
The reason the stock might be interesting is that earnings are currently sitting in a cyclical trough. Bunge earned almost $15 per share in 2023 when commodity markets were booming, but that fell to under $5 last year as margins normalized. Management believes $13 per share is the right "mid-cycle" level once the Viterra benefits fully kick in, and they've set a target of $15 by 2030. If they're even roughly right, the stock at around $105 is trading at only 7-8 times normal earnings - which would be cheap for a company with this kind of market position.
The main thing that could go wrong is that margins don't recover to mid-cycle levels. Chinese tariffs on US soybeans are a real threat, and a state-backed Chinese competitor called COFCO has been steadily eating into the market share of the traditional grain trading giants. There's also the question of whether Glencore, which owns about 16% of Bunge's stock and has hinted it wants to exit agribusiness entirely, will dump shares on the market. If a block that large comes for sale, it could pressure the price. And until Bunge starts generating positive free cash flow again, the generous dividend and buyback promises are being funded from savings rather than earnings - a situation that can't continue indefinitely.
How we got to $87 - $115
Breakdown
Bunge's balance sheet nearly doubled through the Viterra acquisition, expanding from $24.9B in total assets at Q4 2024 to $46.78B at Q2 2026. Total equity stands at $17.34B ($82.70/share book value), with total debt of $15.26B ($5.83B current + $9.43B long-term) yielding a 0.96 D/E ratio. Cash is thin at just $593M, representing only 3.9% of total debt - a sharp decline from the $6.79B cash position at Q2 2025 (pre-Viterra close).
For an agribusiness processor, the key asset fair value question centers on the physical infrastructure: oilseed crushing plants, grain elevators, port terminals, and storage facilities. These assets likely carry replacement values above book, given construction cost inflation and multi-year permitting timelines. The 10-Q notes the Viterra acquisition enhanced the company's global footprint in softseed processing, soybean processing, and grain merchandising [Bunge 10-Q FY2026, SEC].
However, the acquisition also introduced significant goodwill and intangibles that must be scrutinized - the $21.9B jump in total assets against roughly $8.2B deal value suggests substantial balance sheet reclassification. Litigation reserves of $291M in civil claims, $88M in tax claims, and $41M in labor claims [Bunge 10-Q FY2026, SEC] are modest relative to total assets but non-trivial against the $843M net income run rate. The current ratio of 1.57 provides adequate short-term liquidity, though the quick ratio of 0.64 and cash ratio of 0.04 expose reliance on inventory conversion - typical for commodity processors but a vulnerability in a supply chain disruption.
The most concerning data point is negative free cash flow of -$711M, which signals that Bunge is currently consuming rather than generating cash after capital expenditures. This is likely a temporary condition driven by Viterra integration costs and elevated capex, but it means the 2.72% dividend yield ($2.86/share annualized) and newly authorized $3B share repurchase program [Bunge 2026 Investor Day, investors.bunge.com, March 10, 2026] are being funded from the balance sheet rather than operations. The 56.91% payout ratio based on TTM EPS of $5.24 is manageable but leaves little cushion if earnings don't recover.
Management guided net interest expense at $575-625M for 2026 [Bunge Q4 2025 Results, investors.bunge.com, February 4, 2026], representing a significant new burden that was essentially non-existent pre-Viterra. Capital allocation priorities appear to be: (1) debt service, (2) integration capex, (3) dividend maintenance, (4) share repurchases - in that order. The Investor Day commitment to return at least 50% of discretionary cash flow to shareholders [Bunge Investor Day, investors.bunge.com, March 10, 2026] is encouraging but predicated on FCF turning positive.
The sale of the BP Bunge Bioenergia JV stake in October 2024 [Bunge JV Sale, bunge.com, 2024] and pending CJ Selecta acquisition show active portfolio management, though the net direction is adding rather than reducing complexity during an integration period.
Bunge's trailing three-year earnings trajectory tells a story of cyclical decline from a commodity supercycle peak: EPS fell from $14.87 (2023) to $7.99 (2024) to $4.91 (2025), a 67% decline. Revenue followed a V-shape pattern, dropping from $59.5B (2023) to $53.1B (2024) then surging to $70.3B (2025) on the Viterra consolidation, making organic trends hard to parse. Gross margins remain thin at ~5%, typical for commodity processing but offering minimal buffer against cost pressures.
Operating margin compressed from 5.3% (2023) to 3.1% (2024) to 1.8% (2025). On the positive side, quarterly execution has been strong: Bunge beat analyst EPS estimates in 6 of the last 8 quarters, including most recently Q1 2026 ($1.99 vs $1.81 est) and Q2 2026 ($1.83 vs $0.883 est). The Q1 2025 miss ($2.13 vs $2.30 est) was the only material shortfall.
Management raised 2026 adjusted EPS guidance to $9.00-$9.50 from an initial $7.50-$8.00 [Bunge 8-K, SEC, April 29, 2026], and the Investor Day upgraded the mid-cycle EPS baseline from $8.50 (set in 2022) to approximately $13 [Bunge Investor Day, investors.bunge.com, March 10, 2026]. Viterra synergies of $70M in 2025 ran ahead of plan, with $190M expected in 2026 and a $220M annualized run rate by year-end [Bunge Q4 2025 Results, investors.bunge.com, February 4, 2026].
The forward earnings trajectory is the critical variable for Bunge's valuation. The forward P/E of 10.4x implies approximately $10.10 in forward EPS, broadly consistent with the raised $9.00-$9.50 adjusted EPS guidance for 2026 and analyst consensus. The PEG ratio of 0.64 on a 16.35% 5-year growth estimate appears attractive, but this growth rate warrants scrutiny - it is substantially driven by Viterra synergy realization and base-effect recovery from cyclically depressed 2024-2025 earnings rather than organic volume growth.
Sustainable organic growth for a global oilseed processor is closer to the 4-5% CAGR of the underlying fats and oils market [Mordor Intelligence, 2025]. The $15 EPS target by 2030 [Bunge Investor Day, investors.bunge.com, March 10, 2026] implies ~15% CAGR from the $4.91 TTM EPS base, but only ~3.5% CAGR from the $13 mid-cycle baseline - the latter being the more honest growth rate once normalization is complete. Key assumptions: (1) Viterra synergies reach the $220M run rate on schedule, (2) crush margins normalize above the depressed 2024-2025 levels but below the 2023 peak, (3) biofuel demand provides a structural tailwind to oilseed processing volumes, and (4) China tariff risk on US soybeans [China tariff news, Benzinga, March 10, 2025] does not materially disrupt Bunge's global origination network.
The 30/70 first-half/second-half seasonality shift post-Viterra means H2 2026 results will be the real test of the earnings recovery thesis.
Bunge's moat rests on physical infrastructure and scale - oilseed crushing plants, grain elevators, port terminals, and a global origination network that would take a competitor years and billions of dollars to replicate. Post-Viterra, Bunge handles approximately 142 million tons annually, making it the second-largest global agricultural trader behind only Cargill (217M tons) [UkrAgroConsult, 2025-2026]. This scale provides cost advantages in logistics, origination, and processing.
However, the moat is narrowing at the industry level: the ABCD oligopoly's combined market share has declined from 70-90% to 50-60% over the past decade, primarily due to COFCO International's state-backed expansion [UkrAgroConsult, 2025-2026]. Switching costs for farmer suppliers are low, and the end products (soybean meal, vegetable oils) are largely undifferentiated commodities. Bunge's competitive advantage is therefore primarily cost-based and scale-based rather than brand or switching-cost driven.
The biofuel tailwind - renewable diesel and sustainable aviation fuel mandates - creates structural demand for crush capacity that favors incumbents with existing infrastructure. The Chevron partnership to build an oilseed processing plant in Destrehan [Bunge & Chevron Facility, various sources, March 2024] exemplifies this positioning. The moat trend is stable to slightly eroding given competitive pressures, warranting a narrow assessment.
CEO Greg Heckman has delivered credibly since taking the role in 2019: executing the transformative Viterra combination, divesting non-core assets (BP Bioenergia JV, European Margarines and Spreads), running synergies ahead of schedule, and consistently beating quarterly estimates. The mid-cycle EPS baseline upgrade from $8.50 to $13 [Bunge CEO, World Grain, 2026] is a measurable commitment that can be tracked. Insider ownership at 17.3% is exceptionally high for a company of this size, creating strong alignment.
Insider transactions show no open-market sales - only stock awards, which is a positive signal. The board has been refreshed with seven new directors in three years, including Glencore and CPPIB nominees per the Viterra deal terms [Bunge DEF 14A FY2025, SEC, April 2026]. CFO John Neppl has been a stable presence through the integration.
The COO transition in December 2025 [Bunge Leadership Changes, bunge.com, December 2025] from dual co-COOs to sole COO Julio Garros simplifies the reporting structure. Limitations: I cannot assess management's interpersonal dynamics, negotiation skill, or integrity beyond the measurable track record, which on balance is positive.
Several material risks warrant attention. First, commodity cyclicality: crush margins and grain trading spreads are inherently volatile, and the 2023 earnings peak ($14.87 EPS) may have represented a multi-year high. Margins have already compressed significantly.
Second, China trade policy: China imposed tariffs on US soybeans [Benzinga, March 10, 2025], directly threatening Bunge's largest processing segment. While Bunge's global footprint (Brazil, Argentina, Canada, Australia) provides geographic diversification, the US soybean crush business is material. Third, integration execution risk: the Viterra merger is the largest in Bunge's history and combines complex global operations.
While early synergy results are positive, full integration takes 2-3 years. Fourth, balance sheet leverage: the 0.96 D/E ratio and $15.3B total debt are elevated, with $575-625M annual interest expense consuming a meaningful share of operating income. Fifth, Glencore overhang: Glencore holds approximately 16-17% of Bunge and has signaled a potential agriculture industry exit [The Western Producer, 2025-2026], which could pressure the stock if shares are sold in size.
Sixth, litigation reserves of $420M (civil, tax, labor combined) plus a merger-related class action investigation [MarketScreener, undated] create tail risk, though management characterizes all as non-material. The $291M civil claims reserve deserves monitoring.
The global fats and oils market is growing at 4-5% CAGR with estimates ranging from $117B to $484B depending on definition [Mordor Intelligence, 2025; Fortune Business Insights, 2025]. The biofuel-driven demand for vegetable oils and oilseed crush is a genuine secular tailwind - renewable fuel mandates in the US and EU structurally increase demand for Bunge's core processing capacity. The soy protein concentrate market alone is projected to grow from $4.64B to $7.13B by 2035 [Towards FnB, January 23, 2026].
Bunge's positioning within this landscape is strong post-Viterra: the #2 global trader with expanded origination in Canada, Australia, and Eastern Europe. Institutional ownership is robust at 79-89%, with major holders including Vanguard (11.5%), CPPIB (13.1%), and Capital World Investors (8.6%) [Bunge DEF 14A, SEC; WallStreetZen]. Analyst consensus is bullish at 1.5 (between strong buy and buy) with a $145.50 target price, implying 38% upside.
Social sentiment scores are moderate (4.7/5 average). No hostile bids or activist campaigns are active, though the Glencore stake creates latent M&A optionality. ADM's accounting scandals in 2024-2025 may be creating a relative opportunity for Bunge to gain trading counterparty share.